XTRM - XTRM

La vendita allo scoperto per Extreme Biodiesel dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Extreme Biodiesel. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Extreme Biodiesel (OTC:XTRM) Azioni, Report sulle vendite allo scoperto

Extreme Biodiesel Inc is engaged in the acquisition, development and sales of residential real estate in Idaho.

EXTREME BIODIESEL INC by Extreme Biodiesel, Inc.

Extreme Biodiesel Inc

Lineage Cell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LCTX#AMEX">LCTX</a>) will release its quarterly earnings report on Tuesday, 2025-05-13. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Lineage Cell Therapeutics to report an earnings per share (EPS) of $-0.03.
Anticipation surrounds Lineage Cell Therapeutics's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Historical Earnings Performance</h3>
In the previous earnings release, the company beat EPS by $0.01, leading to a 0.36% increase in the share price the following trading session.
Here's a look at Lineage Cell Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.03</td>
<td>-0.03</td>
<td>-0.04</td>
<td>-0.04</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.02</td>
<td>-0.02</td>
<td>-0.03</td>
<td>-0.04</td>
</tr>
<tr>
<td>Price Change %</td>
<td>0.0%</td>
<td>-2.0%</td>
<td>3.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747065929_0_0.png" alt="eps graph" />
<h3>Tracking Lineage Cell Therapeutics's Stock Performance</h3>
Shares of Lineage Cell Therapeutics were trading at $0.44 as of May 09. Over the last 52-week period, shares are down 55.36%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<h3>Analyst Opinions on Lineage Cell Therapeutics</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Lineage Cell Therapeutics.
Analysts have provided Lineage Cell Therapeutics with 5 ratings, resulting in a consensus rating of Buy. The average one-year price target stands at $5.0, suggesting a potential 1036.36% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of and Macrogenics, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Macrogenics, with an average 1-year price target of $2.0, suggesting a potential 354.55% upside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
The peer analysis summary provides a snapshot of key metrics for and Macrogenics, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lineage Cell Therapeutics</td>
<td>Buy</td>
<td>37.36%</td>
<td>$2.71M</td>
<td>-4.53%</td>
</tr>
<tr>
<td>Macrogenics</td>
<td>Neutral</td>
<td>93.47%</td>
<td>$12.24M</td>
<td>-13.06%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Lineage Cell Therapeutics ranks higher than its peers in Revenue Growth and Gross Profit, indicating strong performance in these areas. However, it lags behind in Return on Equity. Overall, Lineage Cell Therapeutics is positioned in the middle compared to its peers based on the provided metrics.
<h3>Discovering Lineage Cell Therapeutics: A Closer Look</h3>
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
<h3>Financial Insights: Lineage Cell Therapeutics</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Lineage Cell Therapeutics's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 37.36%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Lineage Cell Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -114.12%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Lineage Cell Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -4.53% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Lineage Cell Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -3.12% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Lineage Cell Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 0.03, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/LCTX/earnings">To track all earnings releases for Lineage Cell Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

LCTX

Examining the Future: Lineage Cell Therapeutics's Earnings Outlook

WIIM

RMTI

RMTI stock has given up its prior gain. Rockwell Medical shares were trading higher after the company reported better-than-expected Q1 financial results.

RBC Capital analyst Darko Mihelic maintains Sun Life Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLF#NYSE">SLF</a>) with a Outperform and raises the price target from $82 to $88.

News

Price Target

Analyst Ratings

RBC Capital Maintains Outperform on Sun Life Financial, Raises Price Target to $88

The Consumer Price Index for April, due Tuesday morning, could test Wall Street's renewed bullishness after a major U.S.-China tariff rollback<a href="https://www.benzinga.com/government/regulations/25/05/45347089/wall-street-rips-higher-as-tariff-truce-halts-us-china-economic-escalation"> fueled risk-on sentiment. </a>
Despite a slightly defused trade war, the inflation print could tighten the Fed's hand further, especially if prices came in hotter than forecast.
Wall Street economists agree that the annual headline inflation rate will remain at 2.4%—the 49th straight month above the Federal Reserve's 2% target.
Inflation is forecast to rebound from a 0.1% drop in March to 0.3% in April. Core CPI, which excludes food and energy, is expected to rise 0.3% monthly and hold steady at 2.8% annually.
Bank America&#8217;s economist Stephen Juneau warns that "larger increases are in the pipeline" due to front-loaded demand and the lingering impact of April's tariff shock.
See Also: <a href="https://www.benzinga.com/news/earnings/earnings-misses/25/05/45353447/amc-networks-sales-drop-as-analyst-warns-of-continued-pressure-on-revenue">AMC Networks&#8217; Sales Drop As Analyst Warns Of &#8216;Continued Pressure&#8217; On Revenue</a>
<h3 class="wp-block-heading">Fed Rate Cut Expectations Collapse After US-China Trade Truce</h3>
The surprise U.S.-China trade breakthrough on Monday delivered another blow to short-term Fed cut bets. With tariffs slashed by over 100 percentage points for at least 90 days, economic uncertainty tied to supply chains and pricing has decreased. 
Markets now price just an 8% probability of a 25-basis-point cut in June, according to CME FedWatch data. That's down from nearly 40% a week ago. The odds for a July cut stand at 42%, while expectations for two cuts by December have dropped to 72%, from nearly three cuts priced before last week's FOMC meeting.
The Federal Reserve kept rates unchanged for a third consecutive meeting in May and emphasized that "uncertainty about the economic outlook has increased," citing risks of both higher unemployment and persistent inflation. 
Fed Chair Jerome Powell said policy is in a "good place" and the central bank will wait for more clarity on trade and prices.
 "Inflation remains above the Federal Open Market Committee's 2% target, and further progress on disinflation has been slow," said Fed Governor Adriana Kugler on Monday, reinforcing the central bank's cautious stance.
<h3 class="wp-block-heading">Tariffs: A Short-Term Boost To Prices?</h3>
While the U.S.-China truce reduces long-term inflation risk, at least from a supply-side perspective, April may still show upward price pressures as businesses and consumers reacted to the previous tariff escalation. 
Bank of America indicates that tariff revenues and effective rates rose about 2 percentage points in April — a modest but broad-based input cost pressure.
Core goods inflation is expected to rise 0.1% month-over-month after a 0.1% drop in March, driven by front-loaded demand and rising auto prices. Juneau highlighted a 2.7% monthly spike in the Manheim Used Vehicle Value Index as another red flag.
"Tariffs should be a modest boost to goods prices this month," Juneau said, "but larger increases are in the pipeline."
Services inflation may be tamer. The analyst expects a slight moderation in rent inflation and is watching categories like airfares, lodging and car rentals for signs of weakening demand, which is already visible in card spending data.
According to veteran Wall Street investor Ed Yardeni, &#8220;increases like the 2.7% month-over-month jump in the Manheim Used Vehicle Value Index in April from March bear watching.&#8221;
&#8220;Higher prices paid for imports due to tariffs are also driving up service sector firms' costs, feeding through to higher prices, notably in consumer-facing industries such as restaurants and hotels,&#8221; said S&amp;P Global&#8217;s chief economist Chris Williamson in the latest U.S. Services PMI report.
<h3 class="wp-block-heading">What To Expect In Markets</h3>
It's unlikely Tuesday's inflation report derails Wall Street&#8217;s tariff-relief rally—unless the numbers come in well above expectations. 
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) — which tracks the S&amp;P 500 index — surged 2.6% on Monday to an over two-month high on hopes that the trade truce reduces supply-side price pressures and stabilizes global growth.
Still, sticky inflation would signal that the Fed's 2% goal remains distant, reinforcing its higher-for-longer interest rate stance. A hotter April inflation print might strengthen the dollar and increase bond yields.
The U.S. dollar, which weakened during April's tariff escalation, is <a href="https://www.bloomberg.com/quote/BBDXY:IND?sref=TBDibEcD">rebounding</a> as of May 12. Meanwhile, Treasury yields are climbing: the 30-year bond yield hovered at 4.87% on Monday, near its 2025 high of 5%.
Now Read: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/health-care/25/05/45339399/trump-says-prescription-drug-prices-set-to-drop-by-30-to-80-almost-immediately-thanks-to-most-favored-nation-plan-mark-cuban-urges-president-to-force-tran">Trump Says Prescription Drug Prices Set To Drop By 30% To 80% &#8216;Almost Immediately,&#8217; Mark Cuban Urges President To &#8216;Force Transparency&#8217;</a><span class="author" style="box-sizing: border-box; border: 0px solid rgb(229, 231, 235); --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(59,130,246,.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ;"></li>
</ul>
Image: Shutterstock

Analyst Color

Macro Economic Events

Broad U.S. Equity ETFs

Econ #s

Economics

Federal Reserve

ETFs

New Inflation Data Hits Tuesday: Why It Could Kill Fed Rate Cut Hopes

RBC Capital analyst Daniel Perlin maintains Rackspace Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXT#NASDAQ">RXT</a>) with a Sector Perform and lowers the price target from $3 to $2.

RBC Capital Maintains Sector Perform on Rackspace Technology, Lowers Price Target to $2

Molina Healthcare's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) short percent of float has fallen 26.75% since its last report. The company recently reported that it has 954 thousand shares sold short, which is 2.3% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Molina Healthcare Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747065633_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Molina Healthcare has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Molina Healthcare's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Molina Healthcare's peer group average for short interest as a percentage of float is 4.68%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Is Molina Healthcare Gaining or Losing Market Support?

In the current session, the stock is trading at $34.93, after a 4.75% spike. Over the past month, Lincoln National Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNC#NYSE">LNC</a>) stock increased by 15.52%, and in the past year, by 17.42%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1747065630_0.png" alt="Past Year Chart" />

<h3>Lincoln National P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Lincoln National has a lower P/E than the aggregate P/E of 14.87 of the Insurance industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1747065631_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

Price Over Earnings Overview: Lincoln National

Churchill Downs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHDN#NYSE">CHDN</a>) short percent of float has fallen 4.17% since its last report. The company recently reported that it has 1.67 million shares sold short, which is 2.76% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.22 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Churchill Downs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747065628_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Churchill Downs has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Churchill Downs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Churchill Downs's peer group average for short interest as a percentage of float is 5.40%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

CHDN

How Is The Market Feeling About Churchill Downs?

Reliance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RS#NYSE">RS</a>) has outperformed the market over the past 20 years by 6.36% on an annualized basis producing an average annual return of 14.57%. Currently, Reliance has a market capitalization of $15.67 billion. 
Buying $1000 In RS: If an investor had bought $1000 of RS stock 20 years ago, it would be worth $15,094.99 today based on a price of $296.32 for RS at the time of writing.
<h3>Reliance's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747065625_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Did you ever think Grant Cardone, the real estate and business magnate, would <a href="https://www.tiktok.com/@grantcardone/video/7501545634227309867?lang=en">show off his abs</a> in the middle of an interview? That's exactly what happened in a recent TikTok video where he explained how it's easier than people think to become a millionaire.
"You have a better chance of being a millionaire in America than having abs," he proclaimed.&nbsp;
He proceeded to state that there are seven times more people who are millionaires than who have visible abs. Whether you want to be a millionaire, have visible ads, or both, you can achieve meaningful long-term goals with the right approach.
Don't Miss:
<ul class="wp-block-list">
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.30/share!</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
<h2 class="wp-block-heading">Go All-In</h2>
"The 10X Rule" helped catapult Cardone into the spotlight. In that book, he encourages readers to go all-in with their goals. It's easy to show interest or have a good week, but you need a long-term commitment toward your goals.
Cardone also suggests dominating multiple areas of your life instead of only chasing money. He cares about his family, fitness, and businesses. His life wouldn't be as fulfilling if he only prioritized one of those areas.
Having goals in multiple areas of your life can also make you less prone to distractions. If you have a full calendar that allows you to strengthen yourself in multiple areas, you won't have time for vices or unproductive activities.&nbsp;&nbsp;
Trending: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
<h2 class="wp-block-heading">Increase Your Activity</h2>
Cardone isn't a believer in lowering targets to adjust to current circumstances. Instead, he advocates for increasing your activity to make the target more attainable. If you feel like you're falling short on your financial and fitness goals, don't lower them to feel better about your progress. Instead, you review your schedule and look for ways to minimize distractions and be more productive.
"Any target attacked with the right amount of effort within the right amount of time is achievable," Cardone states in his book, "The 10X Rule."
This approach allows you to play offense instead of defense. If you increase your activity, you will likely move closer to your goals. It's better to apply more effort than it is to lower a target. Furthermore, if you lower a target due to thinking it's out of reach, you can fall into that habit moving forward.
See Also: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
<h2 class="wp-block-heading">Set 10X Goals</h2>
You'll have to work hard throughout your life, but it can be more motivating to work toward a 10X Goal. That's the assertion Cardone makes in his book, and you can apply it to any part of your life. For instance, someone who wants to lose weight can set a goal like having visible abs. That's a more rewarding goal, if achieved, and it can motivate the individual to exercise more often.
On the financial front, aiming for a $5 million net worth may motivate you to put in more effort than striving to have a six-figure net worth. The reward is better if you continue working and learning new skills. You will also have to think of better solutions to current obstacles if you set more ambitious goals.&nbsp;
It's possible to have visible ads, become a millionaire, and achieve both in your life with the right mindset. Embracing the 10X mentality can assist you with any goal.
Read Next:
<ul class="wp-block-list">
<li>The team behind $6B+ in licensing deals is now building the next billion-dollar IP empire — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">invest early at $2.25/share.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
</ul>
Image: Shutterstock

Personal Finance

You Have A Better Chance Of Being A Millionaire In America Than Having Abs,' Grant Cardone States While Showing Off That He Has Both

Walt Disney's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) short percent of float has fallen 5.56% since its last report. The company recently reported that it has 21.44 million shares sold short, which is 1.19% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.1 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Walt Disney Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747065623_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Walt Disney has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Walt Disney's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Walt Disney's peer group average for short interest as a percentage of float is 8.70%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Is the Market Bullish or Bearish on Walt Disney?

RBC Capital analyst Maurice Choy maintains Pembina Pipeline (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PPL#TSX">PPL</a>) with a Outperform and lowers the price target from C$65 to C$62.

TSX:PPL

RBC Capital Maintains Outperform on Pembina Pipeline, Lowers Price Target to C$62

Compass Point analyst Ed Engel upgrades Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) from Sell to Neutral.

Upgrades

COIN

Compass Point Upgrades Coinbase Global to Neutral

INHD

INNO HOLDINGS shares are trading higher after the company announced a strategic cooperation with New Life Technology Development on developing a B2B marketplace platform.

RBC Capital analyst Andrew Wong maintains Nutrien (TSX:<a class="ticker" href="https://www.benzinga.com/stock/NTR#TSX">NTR</a>) with a Outperform and raises the price target from C$60 to C$65.

TSX:NTR

RBC Capital Maintains Outperform on Nutrien, Raises Price Target to C$65

RBC Capital analyst Andrew Wong maintains Nutrien (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTR#NYSE">NTR</a>) with a Outperform and raises the price target from $60 to $65.

RBC Capital Maintains Outperform on Nutrien, Raises Price Target to $65

RBC Capital analyst Maurice Choy reiterates Enbridge (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ENB#TSX">ENB</a>) with a Outperform and maintains C$67 price target.

Reiteration

TSX:ENB

RBC Capital Reiterates Outperform on Enbridge, Maintains C$67 Price Target

RBC Capital analyst Maurice Choy reiterates Enbridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENB#NYSE">ENB</a>) with a Outperform and maintains $67 price target.

RBC Capital Reiterates Outperform on Enbridge, Maintains $67 Price Target

Lantronix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRX#NASDAQ">LTRX</a>) reported in-line earnings for the third quarter, <a href="https://www.benzinga.com/quote/LTRX/earnings">after the closing bell on Thursday</a>.
The company posted quarterly earnings of 3 cents per share which met the analyst consensus estimate. The company reported quarterly sales of $28.50 million which missed the analyst consensus estimate of $29.12 million.
&#8220;We&#8217;re positioning Lantronix to lead the next wave of industrial and enterprise transformation at the edge,&#8221; said Saleel Awsare, president and CEO of Lantronix. &#8220;This quarter reflects continued investment in high-growth areas — from AI-enabled gateways to 5G connectivity — while advancing our innovation roadmap, global partnerships and talent base.&#8221;
Lantronix said it sees fourth-quarter adjusted EPS of $0.00-$0.02, versus market estimates of $0.05 Est, and expects sales of $26.50 million-$30.580 million versus expectations of $30.13 million.
Lantronix shares fell 1.4% to trade at $2.07 on Monday.
These analysts made changes to their price targets on Lantronix following earnings announcement.
<ul class="wp-block-list">
<li>Needham analyst Ryan Koontz maintained Lantronix with a Buy and lowered the price target from $5.5 to $4.5.</li>
<li>Canaccord Genuity analyst George Gianarikas maintained the stock with a Buy and lowered the price target from $4.5 to $3.</li>
</ul>
Considering buying LTRX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="593" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12113659/image-129-1024x593.png" alt="" class="wp-image-912121" style="width:542px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12113659/image-129-1024x593.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12113659/image-129-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12113659/image-129-768x445.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12113659/image-129.png 1097w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45348276/marriott-international-to-rally-more-than-17-here-are-10-top-analyst-forecasts-for-monday">Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday</a> </li>
</ul>
Photo via Shutterstock

LTRX

These Analysts Cut Their Forecasts On Lantronix Following Q3 Results

<figure class="wp-block-image aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="683" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073646/Pills-1024x683.jpeg" alt="" class="wp-image-12776" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073646/Pills-1024x683.jpeg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073646/Pills-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073646/Pills-768x512.jpeg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073646/Pills.jpeg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h2 class="wp-block-heading">A Pharma Panic That Could Pay Us</h2>
Executive orders often move markets before move policy is implemented.&nbsp;Late Sunday, President Trump said he'll sign a Most‑Favored‑Nation (MFN) order forcing U.S. payers to match the&nbsp;lowest&nbsp;price any country gets for each prescription drug. Asian investors heard that and immediately slammed Japanese pharma stocks 5‑7 %. If the pattern holds, U.S.‑listed drug makers will open in the red when Wall Street rings the bell.
My read:&nbsp;a&nbsp;knee‑jerk sell‑off would be a gift. The MFN idea died in the courts four years ago and may take months to resurface in enforceable form. Meanwhile, global manufacturers have an obvious counter‑move: pull supply from the handful of ultra‑cheap markets (looking at you, Czech Republic) and re‑launch everywhere at a single, slightly discounted list price. Net revenue changes little; headline risk does all the damage.
Below are the two ways I plan to monetize that dislocation.
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">Company&nbsp;A – Platform Cash&nbsp;Machine With Royalty Armor</h3>
<ul class="wp-block-list">
<li>Fundamentals 
<ul class="wp-block-list">
<li>Piotroski F‑Score&nbsp;9 / 9&nbsp;– pristine balance sheet, rising margins, no accounting red flags.</li>
<li>FY‑24 royalty revenue&nbsp;+27 %&nbsp;y/y; operating cash‑flow margin&nbsp;45 %.</li>
<li>Net debt:&nbsp;$‑170 M&nbsp;(yes, net cash) after another quarter of buybacks.</li>
</ul>
</li>
<li>Technicals 
<ul class="wp-block-list">
<li>Price has stair‑stepped higher since October.&nbsp;</li>
<li>Price is above both 50 and 200 day moving averages&nbsp;– a textbook rising channel.</li>
</ul>
</li>
<li>Why MFN risk is minimal 
<ul class="wp-block-list">
<li>Company&nbsp;A doesn't set list prices; its drug‑delivery platform earns a&nbsp;mid‑single‑digit royalty on&nbsp;net&nbsp;sales&nbsp;paid by its partners.</li>
<li>Those partners are market behemoths—Johnson &amp; Johnson, Inc. (JNJ), Bristol Myers Squibb Company (BMY), Pfizer, Inc. (PFE)—that can afford to yank products from low‑margin jurisdictions until pricing equilibrates.</li>
</ul>
</li>
<li>How I'm playing it 
<ul class="wp-block-list">
<li>Bull‑put credit spread: Taking advantage of expensive puts to collect a net credit which we&#8217;ll get to keep if the stock doesn&#8217;t fall further over the next few months.</li>
<li>Equity kicker: Allocate part of that credit to Jan&nbsp;2026&nbsp;OTM calls. Theta from the spread finances the lottery ticket.</li>
</ul>
</li>
</ul>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">Company&nbsp;B – The Diabetes Moon‑Shot</h3>
This one is a pure speculative bet—but with asymmetric payoff.
<ul class="wp-block-list">
<li>Catalyst 
<ul class="wp-block-list">
<li>First‑in‑human trial just made its debut participant&nbsp;insulin‑independent after 30&nbsp;years of Type‑1 Diabetes. Not only doesn&#8217;t he need to take insulin, but he doesn&#8217;t need to take any immunosuppressant drugs either. No safety issues so far.&nbsp;</li>
</ul>
</li>
<li>Balance sheet 
<ul class="wp-block-list">
<li>~$800 M cash against a ~$400 M annual burn → roughly&nbsp;24&nbsp;months of runway&nbsp;with zero debt.</li>
</ul>
</li>
<li>Risk 
<ul class="wp-block-list">
<li>Biology can always surprise.</li>
<li>FDA hurdles, capital raises if share price pops.</li>
</ul>
</li>
<li>Position sizing 
<ul class="wp-block-list">
<li>Treat as a&nbsp;lotto ticket: less than 1% of portfolio in common shares—small enough to torch without blinking, big enough to matter if the therapy works.</li>
</ul>
</li>
</ul>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">Why I Like The Pair Trade</h3>
<ul class="wp-block-list">
<li>Company&nbsp;A&nbsp;offers steady cash flow, strong technical momentum, and optionality via a low‑cost spread strategy.</li>
<li>Company&nbsp;B&nbsp;is binary, but the upside—an outright cure for T1D—is hard to overstate.</li>
<li>Both should rebound once the MFN headlines fade and investors remember revenue isn't set by social media posts.</li>
</ul>
I have trades&nbsp;teed up&nbsp;for both names. If you'd like to know the tickers and get an alert the moment I pull the trigger, feel free to subscribe to my trading Substack/occasional email list below.&nbsp;
And if you&#8217;d rather limit your risk here, you can download the Portfolio Armor app by&nbsp;aiming your iPhone camera at the QR code below (or by&nbsp;<a href="https://apps.apple.com/us/app/portfolio-armor/id394951144">tapping here</a>, if you&#8217;re reading this on your phone).&nbsp;
<figure class="wp-block-image size-large"><a href="https://apps.apple.com/us/app/portfolio-armor/id394951144"><img loading="lazy" decoding="async" width="1024" height="683" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073752/PA-JPEG-2-1024x683.jpeg" alt="" class="wp-image-12777" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073752/PA-JPEG-2-1024x683.jpeg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073752/PA-JPEG-2-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073752/PA-JPEG-2-768x512.jpeg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073752/PA-JPEG-2.jpeg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
If you&#8217;d like to stay in touch
You can scan for optimal hedges for individual securities, find our current top ten names, and&nbsp;create hedged portfolios&nbsp;on&nbsp;<a href="https://portfolioarmor.com/">our website</a>.&nbsp;You can also follow Portfolio Armor on X&nbsp;<a href="https://twitter.com/portfolioarmor">here</a>, or become a free subscriber to <a href="https://portfolioarmor.substack.com/">our trading Substack</a> using the link below (we&#8217;re using that for our occasional emails now).
<figure class="wp-block-image aligncenter size-full"><a href="https://portfolioarmor.substack.com/"><img loading="lazy" decoding="async" width="581" height="372" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073956/Widget-2.jpg" alt="" class="wp-image-12778" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073956/Widget-2.jpg 581w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12073956/Widget-2-300x192.jpg 300w" sizes="(max-width: 581px) 100vw, 581px" /></a></figure>

Comments

Extreme Biodiesel

Vendite allo scoperto

Extreme Biodiesel (OTC:XTRM) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO